UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Recruitment status Completed
Unique ID issued by UMIN UMIN000013050
Receipt No. R000015213
Official scientific title of the study Angiotensin receptor blocker/Calcium antagonist combination therapy on diurnal blood pressure variation
Date of disclosure of the study information 2014/02/03
Last modified on 2017/05/30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Angiotensin receptor blocker/Calcium antagonist combination therapy on diurnal blood pressure variation
Title of the study (Brief title) Angiotensin receptor blocker/Calcium antagonist combination therapy on diurnal blood pressure variation
Region
Japan

Condition
Condition Hypertension
Classification by specialty
Cardiology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 1) To examine the effects of AIMIX(R) combination tablet (Amlodipine 10mg/Irbesartan 100mg) therapy on blood pressure reduction and organ damage protection and to document side effects.

2) To document the proportion of extreme-dipper, dipper, non-dipper and riser in the patients who are poorly controlled hypertension (clinic systolic BP more than or equal to 140/90 mm Hg despite the combination therapy with Calcium antagonist [Amlodipine 5mg] and angiotensin II receptor antagonist [any one of the following drugs: losartan 50mg, valsartan 80mg, candesartan 8mg, telmisartan 40mg, olmesartan 20mg, azilsartan 20mg]).

3) To document the proportion of extreme-dipper, dipper, non-dipper and riser in patients treated with AIMIX(R) combination tablet.

Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes - Target blood pressure reduction rate (clinic blood pressure less than 140/90 mm Hg ).
- To document the proportion of extreme-dipper, dipper, non-dipper and riser (diurnal blood pressure variation).
Key secondary outcomes - Target blood pressure achievement rate and blood pressure lowering level at the final assessment.
- Change in serum creatinine level (e-GFR) and microalbumin level.
*eGFR(mL/min/1.73m2) = 194 X Cr -1.094 X age -0.287 X Cr -1.154 (X 0.739 for women)
- Change in highly sensitive cardiac troponin T (hs-cTnT), NT-proBNP.

In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field.

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 AIMIX(R) combination tablet
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required.

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients who meet all of the following criteria:
Patients aged 20 years old and over.
Patients who have clinic systolic BP more than or equal to 140/90 mm Hg despite the combination therapy with Calcium antagonist (Amlodipine 5mg) and angiotensin II receptor antagonist (any one of the following drugs: losartan 50mg, valsartan 80mg, candesartan 8mg, telmisartan 40mg, olmesartan 20mg, azilsartan 20mg).
Key exclusion criteria Patients who meet one of the following criteria are excluded:
1) Secondary hypertension
2) Congestive heart failure; onset of acute myocardial infarction in the past 6 month; onset of cerebrovascular disturbance in the past 6 month; current atrial fibrillation or atrioventricular block or severe arrhythmia.
3) hepatic insufficiency (AST or ALT >X2 the upper limit of the normal range) , renal insufficiency (serum Crl.>1.5mg/dL)
4) Diabetic patients being treated with aliskiren.
5) Allergy or drug hypersensitivity.
6) Lack of the informed consent for any reason (e.g. dementia).
7) Women suspected of being pregnant.
8) Patients being ineligible by the attending physicians.
Target sample size 200

Research contact person
Name of lead principal investigator Kazuomi Kario
Organization Jichi Medical University School of Medicine
Division name Division of Cardiovascular Medicine,
Address 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0498, JAPAN
TEL 0285-44-2130
Email kkario@jichi.ac.jp

Public contact
Name of contact person Satoshi Hoshide
Organization Jichi Medical University School of Medicine
Division name Division of Cardiovascular Medicine,
Address 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0498, JAPAN
TEL 0285-44-2130
Homepage URL
Email hoshide@jichi.ac.jp

Sponsor
Institute Jichi Medical University School of Medicine
Institute
Department

Sponsor means an organization that is responsible for plan, deployment and
report of the research including funding management. It doesn't mean
funding agency". Therefore, all clinical trial should have the one.

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2014 Year 02 Month 03 Day

Progress
Recruitment status Completed
Date of protocol fixation
2013 Year 12 Month 09 Day
Anticipated trial start date
2014 Year 02 Month 03 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2014 Year 02 Month 03 Day
Last modified on
2017 Year 05 Month 30 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015213


Contact us.